All Stories

  1. Artificial Intelligence for Tuberculosis Screening and Detection: From Evidence to Policy and Implementation
  2. Optimizing Respiratory Care with NEXThaler: Bridging Technology and Treatment
  3. Allergen Sensitization in Atopic Dermatitis: Distinction from Controls and Prediction of Respiratory Allergies
  4. Artificial Intelligence for Tuberculosis Screening and Detection: From Evidence to Policy and Implementation
  5. Pulmonary diffusing capacity for nitric oxide in disease: a scoping review
  6. Real-world use of beclometasone dipropionate and formoterol fumarate NEXThaler® and asthma control among adult asthmatic patients in Europe: The results of the Newton study
  7. The Impact of Vaccination on COVID-19 Outcomes in Vietnam
  8. Measuring exhaled nitric oxide in COPD: from theoretical consideration to practical views
  9. Deciphering Alveolo-Capillary Gas Transfer Disturbances in Patients Recovering from COVID-19 Lung Disease
  10. Reconciling the past and considering the future of pulmonary function test interpretation
  11. ERS technical standard: Global Lung Function Initiative reference values for exhaled nitric oxide fraction (FENO50)
  12. Cardiopulmonary exercise testing of patients with obstructive sleep apnoea
  13. COPD Patients with Asthma Features in Vietnam: Prevalence and Suitability for Personalized Medicine
  14. GINA Implementation Improves Asthma Symptoms Control and Lung Function: A Five-Year Real-World Follow-Up Study
  15. Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation
  16. Implications of the new ERS/ATS standards on the interpretation of lung function tests
  17. Physical activity, COVID-19, and respiratory comorbidities: The good, the bad, and the ugly
  18. Distal Lung Inflammation Assessed by Alveolar Concentration of Nitric Oxide Is an Individualised Biomarker of Severe COVID-19 Pneumonia
  19. Open-Source Hardware May Address the Shortage in Medical Devices for Patients with Low-Income and Chronic Respiratory Diseases in Low-Resource Countries
  20. Pulmonologists collaborate with explainable artificial intelligence for superior interpretation of pulmonary function tests
  21. Usefulness of day-one chest X-ray score for predicting mortality and ICU admission in COVID-19 patients
  22. How Artificial Intelligence in Imaging Can Better Serve Patients with Bronchial and Parenchymal Lung Diseases?
  23. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
  24. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
  25. Usefulness of Hospital Admission Chest X-ray Score for Predicting Mortality and ICU Admission in COVID-19 Patients
  26. The Role of Blood Gas Analysis in the Post-Acute Phase of COVID-19 Pneumonia
  27. European Respiratory Society statement on long COVID follow-up
  28. A Low-Cost, Easy-to-Assemble Device to Prevent Infant Hyperthermia under Conditions of High Thermal Stress
  29. Reply to Jain: Olfactory Nitric Oxide Link in COVID-19: A Marker of Neurogenesis or Risk Factor for Chronic Rhinosinusitis?
  30. Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network
  31. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease
  32. Computed tomography after severe COVID-19 pneumonia: findings at 6 months and beyond
  33. Late Breaking Abstract - Real world patient-reported outcomes in asthma across six European countries: the NEWTON study
  34. Stepping down for mild asthma and disadvantages of the ‘as‐needed’ strategy—Perspectives from a developing country
  35. Persistent Nasal Inflammation 5 Months after Acute Anosmia in Patients with COVID-19
  36. Chronic Lung Allograft Dysfunction Post Lung Transplantation: A Review of Computed Tomography Quantitative Methods for Detection and Follow-Up
  37. Guideline directed management of COVID-19: Do's and Dont's
  38. Improving lung health in low-income and middle-income countries: from challenges to solutions
  39. Lack of essential medical resources leaves Africa breathless
  40. Modeling of Gas Exchange in the Lungs
  41. Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies
  42. Elastic Registration–driven Deep Learning for Longitudinal Assessment of Systemic Sclerosis Interstitial Lung Disease at CT
  43. Guidance production before evidence generation for critical issues: the example of COVID-19
  44. Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID‐19
  45. A new method to estimate the long-term effect of immunosuppressants and vasodilator therapies on lung function outcomes in systemic sclerosis patients
  46. Deep Learning–based Approach for Automated Assessment of Interstitial Lung Disease in Systemic Sclerosis on CT Images
  47. Tracking disease progression in COPD with pulmonary function tests
  48. FENO as a biomarker guide for inhaled corticosteroid step down in patients with mild-to-moderate well-controlled asthma
  49. Low Cost Mechanical Ventilator for Emerging Economies: Open-Source Hardware Description and Bench Test Performance
  50. Low-cost, easy-to-build noninvasive pressure support ventilator for under-resourced regions: open source hardware description, performance and feasibility testing
  51. Individual modeling of oxygen capture by the human lungs
  52. Introduction of a new approach to interpret pulmonary function tests (PFT) based on Machine learning and Game theory
  53. A Novel Modelling Framework Using Deep Neural Network to Build Reference Values for Pulmonary Function Tests
  54. Of the need to reconcile discrepancies between two different reference equations for combined single-breath DLNO–DLCO in systemic sclerosis
  55. Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis
  56. Late Breaking Abstract - MIF inhibition in a murine model of bleomycin-induced lung fibrosis
  57. Prediction of individual cardiac output from measured VO2 and ventilation
  58. The cost and benefits of exhaled nitric oxide (NO) measurement in asthma - The results from three years follow-up study
  59. Effect of NAPDH oxidase inhibitors on lung fibroblast proliferation in systemic sclerosis
  60. Recommandations pour le test de provocation bronchique à la méthacholine en pratique clinique, à partir de l’âge scolaire
  61. Global Lung Initiative equations for pulmonary hypertension screening in systemic sclerosis
  62. Basic and translational research in the European Respiratory Journal
  63. ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update
  64. Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases
  65. Physiology of the lung in idiopathic pulmonary fibrosis
  66. Étude de la prévalence du syndrome d’apnées obstructives du sommeil au Vietnam
  67. High Baseline Serum Clara Cell 16 kDa Predicts Subsequent Lung Disease Worsening in Systemic Sclerosis
  68. Combined measurement of carbon monoxide and nitric oxide lung transfer does not improve the identification of pulmonary hypertension in systemic sclerosis
  69. Effects of growth and aging on the reference values of pulmonary nitric oxide dynamics in healthy subjects
  70. The DL NO /DL CO ratio: Physiological significance and clinical implications
  71. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement
  72. A European Respiratory Society technical standard: exhaled biomarkers in lung disease
  73. Study of nasal exhaled nitric oxide levels in diagnosis of allergic rhinitis in subjects with and without asthma
  74. Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)
  75. Standardisation and application of the single-breath determination of nitric oxide uptake in the lung
  76. Utilising exhaled nitric oxide information to enhance diagnosis and therapy of respiratory disease – current evidence for clinical practice and proposals to improve the methodology
  77. The ambition of the European Respiratory Journal continues: chapter 5
  78. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle
  79. Building bridges for innovation in ageing: Synergies between Action Groups of the EIP on AHA
  80. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis
  81. Should we use gait speed in COPD, FEV1in frailty and dyspnoea in both?
  82. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)
  83. Is exhaled nitric oxide a marker of air pollution effect?
  84. Clinical trials: registration and transparency: TABLE 1
  85. AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation
  86. Deriving information from external Big Databases and Big Data analytics: all that glitters is not gold
  87. RhoA/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis
  88. Inhaled nitric oxide decreases pulmonary endothelial nitric oxide synthase expression and activity in normal newborn rat lungs
  89. Study of Exhaled Nitric Oxide in Subjects with Suspected Obstructive Sleep Apnea: A Pilot Study in Vietnam
  90. The ambition of the ERJ: chapter 4
  91. High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation
  92. Nitrogen monoxide and carbon monoxide transfer interpretation
  93. Should we monitor exhaled NO to assess the restoration of CFTR function in CF patients?
  94. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation
  95. A study of exhaled NO (FENO) measurement used to determine asthma control, dose of inhaled corticosteroid and cost in a developing country
  96. «Big Data» et pneumologie
  97. Increased exhaled nitric oxide precedes lung fibrosis in two murine models of systemic sclerosis
  98. Cellular and molecular mechanisms in the pathophysiology of systemic sclerosis
  99. Contribution of exhaled nitric oxide measurement in airway inflammation assessment in asthma. A position paper from the French Speaking Respiratory Society
  100. Increased alveolar nitric oxide concentration is related to nocturnal oxygen desaturation in obstructive sleep apnoea
  101. Cardiovascular comorbidities in obstructive sleep apnoea according to age: a sleep clinic population study
  102. The ambition of the ERJ: chapter 3
  103. How to Assess Alveolar Nitric Oxide
  104. Intérêts des explorations fonctionnelles respiratoires et des études des biomarqueurs dans le diagnostic et le suivi évolutif de la pneumopathie interstitielle diffuse dans la sclérodermie systémique
  105. Le microbiome et les microbiotes respiratoires : des germes et des hommes
  106. Fasudil inhibits prostate cancer-induced angiogenesis in vitro
  107. The role of the RhoA/Rho kinase pathway in anti‑angiogenesis and its potential value in prostate cancer (Review)
  108. Exhaled NO predicts cyclophosphamide response in scleroderma-related lung disease
  109. Integrated care pathways for airway diseases (AIRWAYS-ICPs)
  110. Exhaled nitric oxide concentration and decompression-induced bubble formation: An index of decompression severity in humans?
  111. Early inhaled nitric oxide at high dose enhances rat lung development after birth
  112. Inhaled NO prevents hyperoxia-induced white matter damage in neonatal rats
  113. Prognostic value of six minute walk test in cystic fibrosis adults
  114. Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation
  115. Activation of RhoA/Rho-kinase pathway accounts for pulmonary endothelial dysfunction in patients with chronic obstructive pulmonary disease
  116. Parité des sexes et maladies respiratoires
  117. Pathophysiology Updates for Chronic Obstructive Pulmonary Disease
  118. Évolution de la plèvre : de l’anatomie à la physiologie, à travers l’exemple de l’éléphant
  119. Amelioration of Systemic Fibrosis in Mice by Angiotensin II Receptor Blockade
  120. Role of Rho-kinase and its inhibitors in pulmonary hypertension
  121. High alveolar concentration of nitric oxide is associated with alveolitis in scleroderma
  122. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance
  123. Physiology in respiratory medicine
  124. The editors' farewell and a confident look back to the future
  125. Biologie des systèmes complexes et métabolomique appliqués à la pneumologie
  126. Hypertension pulmonaire : de la physiopathologie moléculaire aux anomalies hémodynamiques
  127. Measuring exhaled nitric oxide in animal models: methods and clinical implications
  128. ERS publications: the flagship and the fleet
  129. A model to predict short-term death or readmission after intensive care unit discharge
  130. Effect of nitric oxide on epithelial ion transports in noncystic fibrosis and cystic fibrosis human proximal and distal airways
  131. Inhaled NO Protects Cerebral White Matter in Neonatal Rats with Combined Brain and Lung Injury
  132. European Union Standards for Tuberculosis Care
  133. Editores e editorialistas: Remando no mesmo barco
  134. Prof. Paul Sadoul, 1918–2011
  135. The European Respiratory Journal makes COPD a priority
  136. Alveolar concentration of nitric oxide predicts pulmonary function deterioration in scleroderma
  137. Autophagie et maladies respiratoires
  138. Whistleblowers
  139. Nitric oxide activity through guanylate cyclase and phosphodiesterase modulation is impaired in fetal lambs with congenital diaphragmatic hernia
  140. ERJ peer reviewers: does this pillar of the Journal's quality need help?
  141. Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis
  142. Clopidogrel protects from cell apoptosis and oxidative damage in a mouse model of renal ischaemia-reperfusion injury
  143. Role of nitric oxide synthases in elastase-induced emphysema
  144. Le vieillissement pulmonaire : de la sénescence cellulaire au déclin de la fonction respiratoire
  145. Le sixième Congrès de pneumologie et de chirurgie thoracique de l’Association franco-vietnamienne de pneumologie : avant-propos
  146. Increased Alveolar Concentration of Nitric Oxide Is Related to Serum-induced Lung Fibroblast Proliferation in Patients with Systemic Sclerosis
  147. The making of the ERJ: behind the scenes and Editors' cut
  148. Increased Rho-kinase expression and activity and pulmonary endothelial dysfunction in smokers with normal lung function
  149. Multicentre trial evaluating alveolar NO fraction as a marker of asthma control and severity
  150. From the Editors:
  151. Stereology: a bridge to a better understanding of lung structure and function
  152. Les nouvelles recommandations internationales de l’hypertension pulmonaire
  153. Impact factor and its role in academic promotion
  154. Le nouveau souffle de l’acide ribonucléique (ARN) en pathologie respiratoire
  155. Study of prone positioning to reduce ventilator-associated pneumonia in hypoxaemic patients
  156. Impact Factor and its Role in Academic Promotion
  157. Refining the changes. Or, how to modify the shape, not the spirit
  158. Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases
  159. Lack of Specificity of the 6-Minute Walk Test as an Outcome Measure for Patients with Systemic Sclerosis
  160. Exhaled nitric oxide, but not serum nitrite and nitrate, is a marker of interstitial lung disease in systemic sclerosis
  161. Exhaled Nitric Oxide in Cystic Fibrosis: Relationships with Airway and Lung Vascular Impairments.
  162. Détection précoce de la bronchopneumopathie chronique obstructive post-tabagique au Viet Nam
  163. Exhaled nitric oxide in cystic fibrosis: relationships with airway and lung vascular impairments
  164. The ERJ in its 21st year of age: a smooth transition for an everlasting evolution
  165. Exercise-induced asthma
  166. Congenital diaphragmatic hernia: current status and review of the literature
  167. Modifications épigénétiques et maladies respiratoires : départager l’inné et l’acquis
  168. Pulmonary hypertension: basic concepts and practical management
  169. Neuronal nitric oxide synthase does not contribute to the modulation of pulmonary vascular tone in fetal lambs with congenital diaphragmatic hernia (nNOS in CDH lambs)
  170. Offline Exhaled Nitric Oxide in Emergency Department and Subsequent Acute Asthma Control
  171. TEP-TDM-FDG et diagnostic de malignité des nodules et masses pulmonaires
  172. VENTILATION-INDUCED PULMONARY VASODILATATION IN LAMBS WITH CONGENITAL DIAPHRAGMATIC HERNIA IS MODULATED BY NITRIC OXIDE
  173. O58. Exhaled NO and inflammatory disorders affecting lung alveoli and the distal airways
  174. The association of vascular endothelial growth factor receptor-1 with the risk of cancer progression following radical prostatectomy
  175. O62. Effects of inhaled nitric oxide on normal rat lung development
  176. P115. Pulmonary endothelial dysfunction in chronic obstructive pulmonary disease post-cigarette smoking: Role of NO synthase and Rho-kinase
  177. Translational research in respiratory medicine
  178. Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer
  179. The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy
  180. L’hypertension artérielle pulmonaire : de nouveaux concepts pour une « vieille » maladie
  181. Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide
  182. Role of ATP-Dependent Potassium Channels in Pulmonary Vascular Tone of Fetal Lambs With Congenital Diaphragmatic Hernia
  183. Role of vascular endothelial growth factor in prostate cancer
  184. Perfusion pulmonaire, espace mort physiologique et hypertension artérielle pulmonaire à l’exercice : la course au recrutement
  185. Signalisation cellulaire et physiopathologie de l’hypertension artérielle pulmonaire
  186. Reduced exhaled NO is related to impaired nasal potential difference in patients with cystic fibrosis
  187. Pulmonary arterial hypertension
  188. Serum levels of vascular endothelial growth factor in patients undergoing prostate biopsy for suspicion of prostate cancer
  189. Inhaled nitric oxide therapy in adults: European expert recommendations
  190. High levels of endogenous nitric oxide produced after burn injury in rats arrest activated T lymphocytes in the first G1 phase of the cell cycle and then induce their apoptosis
  191. Developmental Expression of Vasoactive and Growth Factors in Human Lung. Role in Pulmonary Vascular Resistance Adaptation at Birth
  192. Neutralizing Ceramide: A Major Breakthrough or Yet Another Marginal Target for the Treatment of Acute Lung Injury?
  193. Physiologie respiratoire
  194. Pro PSA : a “pro cancer” form of PSA?
  195. The hepatopulmonary syndrome: NO way out?
  196. From the authors
  197. Respiratory monitoring: revisiting classical physiological principles with new tools
  198. Adrenomedullin: a smart road from pheochromocytoma to treatment of pulmonary hypertension
  199. Noninvasive Assessment of Fetal Pulmonary Blood Flow in Experimental Pulmonary Hypertension in the Fetal Lamb
  200. Combination therapy for pulmonary arterial hypertension: still more questions than answers
  201. The hepatopulmonary syndrome: NO way out?: Fig. 1.—
  202. Nitric oxide synthase 1 as a potential modifier gene of decline in lung function in patients with cystic fibrosis
  203. Systemic arteriovenous fistula leads to pulmonary artery remodeling and abnormal vasoreactivity in the fetal lamb
  204. Involvement of Ca2+/calmodulin-dependent protein kinase II in endothelial NO production and endothelium-dependent relaxation
  205. Nitric oxide inhibits spleen cell proliferative response after burn injury by inducing cytostasis, apoptosis, and necrosis of activated T lymphocytes: role of the guanylate cyclase
  206. Altered myosin isoform expression in rat skeletal muscles induced by a changed thyroid state
  207. Severe pulmonary hypertension: walking through new paths to revisit an old field
  208. Involvement of Na+/Ca2+exchanger in endothelial NO production and endothelium-dependent relaxation
  209. Successful Cardiopulmonary Resuscitation After Cardiac Arrest as a "Sepsis-Like" Syndrome
  210. Altered Guanylyl-Cyclase ActivityIn Vitroof Pulmonary Arteries from Fetal Lambs with Congenital Diaphragmatic Hernia
  211. Role of tyrosine phosphatase in the modulation of pulmonary vascular tone
  212. The effect of a systemic arteriovenous fistula on the pulmonary arterial blood pressure in the fetal sheep
  213. Restoring Effects of Vitamin A on Surfactant Synthesis in Nitrofen-induced Congenital Diaphragmatic Hernia in Rats
  214. Role of Nitric Oxide in Hepatopulmonary Syndrome in Cirrhotic Rats
  215. Decreased Pulmonary and Tracheal Smooth Muscle Expression and Activity of Type 1 Nitric Oxide Synthase (nNOS) after Ovalbumin Immunization and Multiple Aerosol Challenge in Guinea Pigs
  216. Exhaled and Nasal Nitric Oxide as a Marker of Pneumonia in Ventilated Patients
  217. Treatment with 815-nm diode laser induces long-lasting expression of 72-kDa heat shock protein in normal rat skin
  218. Contrasting effects of NO and peroxynitrites on HSP70 expression and apoptosis in human monocytes
  219. Measurement of nitric oxide, nitrite and nitrate using a chemiluminescence assay:an update for the year 2000
  220. Maturational changes of endothelial vasoactive factors and pulmonary vascular tone at birth
  221. Maturational changes of endothelial vasoactive factors and pulmonary vascular tone at birth
  222. The effect of zafirlukast on repetitive exercise–induced bronchoconstriction: The possible role of leukotrienes in exercise-induced refractoriness☆☆☆★
  223. Rôle de la monoxyde d'azote synthase-III et du guanosine 3':5'-monophosphate cyclique dans la protection exercée par le monoxyde d'azote lors d'une ischémie-reperfusion hépatique
  224. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial
  225. Vitamin A decreases the incidence and severity of nitrofen-induced congenital diaphragmatic hernia in rats
  226. Inhaled and exhaled nitric oxide
  227. Effect of Vitamin A on Experimental Congenital Diaphragmatic Hernia (CDH) in Rats
  228. Endothelium-derived nitric oxide and vascular physiology and pathology
  229. Le Club NO
  230. Measuring exhaled nitric oxide: not only a matter of how--but also why--should we do it?
  231. Nitric Oxide Deficiency in Fenfluramine- and Dexfenfluramine-induced Pulmonary Hypertension
  232. Congenital Diaphragmatic Hernia
  233. Disease-related response to inhaled nitric oxide in newborns with severe hypoxaemic respiratory failure
  234. Molecular identification of the role of voltage-gated K+ channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes.
  235. Effects of Muscimol or Homotaurine on Sleep–Wake States in Alcohol-Dependent Rats During Withdrawal
  236. Blood gas measurement during exercise: a comparative study between arterialized earlobe sampling and direct arterial puncture in adults
  237. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost
  238. Monoxyde d'azote (NO) et asthme
  239. Prix Nobel de médecine 1998,Robert F. Furchgott, Louis J. Ignarro, Ferid Murad, Nobel 98 : la part belle au NO
  240. Right Ventricular Function in ALI and ARDS
  241. The use, and misuse, of exogenous endothelial-derived vasodilators in acute respiratory failure
  242. Le NO inhalé en pédiatrie: une molécule peut-elle en cacher une autre?
  243. Étude dy système NO/GMPc endothéliale dans le modèle ovin de hernie diaphragmatique congénital
  244. Rôles des facteurs vasoactifs synthétisés par l'endothélium dans l'hypertension artérielle pulmonaire
  245. Induction of stress proteins by tobacco smoke in human monocytes: modulation by antioxidants
  246. NO et hypertension artérielle pulmonaire
  247. Exhaled nitric oxide during acute changes of airways calibre in asthma
  248. Is arterialized earlobe blood PO2 an acceptable substitute for arterial blood PO2?
  249. Hyporeactivity of mesenteric resistance arteries in portal hypertensive rats
  250. Role of NO in the pulmonary artery hyporeactivity to phenylephrine in experimental biliary cirrhosis
  251. Clinical Significance of the Pulmonary Vasodilator Response During Short-term Infusion of Prostacyclin in Primary Pulmonary Hypertension
  252. Le monoxyde d'azote: un médiateur ubiquitaire
  253. Monoxyde d'azote et régulation de la circulation pulmonaire fœtale et néonatale
  254. Endogenous pulmonary nitric oxide production measured from exhaled air is increased in patients with severe cirrhosis
  255. Endothelial modulation of vasoconstrictor responses to endothelin‐1 in human placental stem villi small arteries
  256. Effect of inhaled nitric oxide on right ventricular function in adult respiratory distress syndrome.
  257. In vitrocontractile and relaxant responses of human resistance placental stem villi arteries of healthy parturients: role of endothelium
  258. Effects of pretreatment with inhaled methoxamine on bronchial responses to histamine in asthmatic subjects
  259. Protective effects of hsp70 in inflammation
  260. Accuracy assessment for three fiberoptic pulmonary artery catheters for $$S\bar vO_2 $$ monitoring
  261. Lack of efficacy of inhaled nitric oxide in ARDS
  262. Echocardiographic investigation of inhaled nitric oxide in newborn babies with severe hypoxaemia
  263. Absence of nitric oxide in airways of ventilated patients
  264. Rôles du NO en physiopathologie cardiovasculaire et respiratoire
  265. Locally deposited but not inhaled frusemide reduces nasal potential difference in healthy subjects
  266. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension.
  267. Inhaled Nitric Oxide for the Adult Respiratory Distress Syndrome
  268. Impairment of pulmonary‐artery endothelium‐dependent relaxation in chronic obstructive lung disease is not due to dysfunction of endothelial cell membrane receptors nor to l‐arginine deficiency
  269. Measurement of nitrogen dioxide formation from nitric oxide by chemiluminescence in ventilated children
  270. α-Adrenoceptor stimulation of porcine pulmonary arteries
  271. In Vitro Pulmonary Vasorelaxant Effect of the Phosphodiesterase Inhibitor Enoximone
  272. Effect of Airway Blood Flow on Airflow
  273. Cyclosporin treatment and nitric oxide release in human coronary arteries.
  274. Relationship between Chronic Hypoxia and In Vitro Pulmonary Relaxation Mediated by Endothelium-Derived Relaxing Factors in Human Chronic Obstructive Lung Disease
  275. Exercise increases the release of atrial natriuretic peptide in heart transplant recipients
  276. Endothelium-derived relaxing factor and the pulmonary circulation
  277. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension
  278. Impairment of Endothelium-Dependent Pulmonary-Artery Relaxation in Chronic Obstructive Lung Disease
  279. Bronchial effects of α-adrenoceptor antagonists in asthma
  280. Endothelial dysfunction in vascular disease
  281. Bronchial blood flow and microvascular permeability in the pathophysiology of asthma
  282. Comparative effects of long-term treatment with prostacyclin and its analogue, iloprost, on exercise tolerance of patients with primary pulmonary hypertension
  283. Validation of impedance cardiography measurements of cardiac output during limited exercise in heart transplant recipients
  284. Exercise-induced asthma as a vascular phenomenon
  285. Effects of SK&F 104353, a leukotriene receptor antagonist, on the bronchial responses to histamine in subjects with asthma: A comparative study with terfenadine
  286. Primary pulmonary hypertension: diagnosis, medical and surgical treatment
  287. Rilmenidine
  288. Impairment of pulmonary endothelium‐dependent relaxation in patients with Eisenmenger's syndrome
  289. Inhaled Terbutaline Administered via a Spacer Fully Prevents Exercise-Induced Asthma in Young Asthmatic Subjects: A Double-Blind, Randomized, Placebo-Controlled Study
  290. Bronchial effects of alpha2-adrenoceptor agonists and of other antihypertensive agents in asthma
  291. Non-Prostanoid Endothelium-Derived Vasoactive Factors
  292. Reduced endothelium-dependent relaxation of cystic fibrosis pulmonary arteries
  293. Comparative effects of rilmenidine and clonidine on bronchial responses to histamine in asthmatic subjects.